Will MorphoSys Trade Profitability for More Products, More Opportunities, and More Risk?
Executive SummaryMorphosys is a rare biotech company in that it is both an R&D driven enterprise and is profitable at the same time, thanks mostly to a variety of antibody discovery deals it has signed over the years with pharmaceutical partners. As the company brings more product candidates into the clinic will its profitability become a strategic liability, imposing limits on how much it can spend to drive products forward?
You may also be interested in...
MorphoSys’s ambition to grow a proprietary pipeline got a boost with FDA giving its lead compound MOR208 fast track status for the treatment of relapsed or refractory diffuse large B-cell lymphoma.
Flush with funds from new partnering deals and recent capital injections, German biotech MorphoSys plans to boost its already considerable R&D spending to build value in the pipeline while holding on to promising assets longer.
MorphoSys sells some of its assets in an effort to concentrate on its proprietary therapeutic endeavors – including a mid-stage rheumatoid arthritis drug.